Welcome to our dedicated page for Travere Therapeutics news (Ticker: TVTX), a resource for investors and traders seeking the latest updates and insights on Travere Therapeutics stock.
News and updates for Travere Therapeutics, Inc. (TVTX) center on its work as a biopharmaceutical company focused on rare kidney, liver and metabolic diseases. Company announcements frequently highlight progress with FILSPARI (sparsentan), an oral, non-immunosuppressive therapy approved to slow kidney function decline in adults with primary IgA nephropathy (IgAN), and under supplemental FDA review as a potential treatment for focal segmental glomerulosclerosis (FSGS).
Investors following TVTX news can track regulatory milestones such as FDA review timelines, PDUFA target action dates and review extensions for the FILSPARI sNDA in FSGS. Travere also reports new clinical data from the Phase 3 DUPLEX and Phase 2 DUET studies in FSGS, as well as from PROTECT, SPARTAN and real-world analyses in IgAN. These updates often focus on proteinuria reduction, kidney function outcomes and correlations between biomarker changes and long-term kidney failure risk.
Travere’s news flow includes financial results and preliminary revenue updates, typically furnished via press releases and Form 8‑K filings, along with commentary on commercial performance of FILSPARI in IgAN. The company also issues releases on pipeline developments, including the planned restart of the pivotal Phase 3 HARMONY Study of pegtibatinase for classical homocystinuria (HCU) and long-term metabolite reduction data from the COMPOSE study.
Additional news items cover partnership activities with CSL Vifor and Renalys Pharma, anticipated regional filings and launches, and Travere’s participation in major medical and investor conferences such as the American Society of Nephrology Kidney Week and large healthcare investment meetings. This page aggregates these developments so readers can follow how clinical, regulatory, commercial and partnership events may shape the company’s rare disease portfolio over time.
Travere Therapeutics (NASDAQ: TVTX) reported fourth-quarter and full-year 2025 results with significant commercial momentum for FILSPARI (sparsentan) and progress in clinical programs. U.S. net product sales were $126.6M in Q4 and $410.5M for full year 2025; FILSPARI sales were $103.3M in Q4 and $322.0M for the year. The company reported a GAAP full-year net loss of $25.5M and non-GAAP net income of $81.1M. The FDA has set a PDUFA target action date of April 13, 2026 for FILSPARI in FSGS. Enrollment resumed in the Phase 3 HARMONY study for pegtibatinase in classical HCU.
Travere Therapeutics (NASDAQ: TVTX) will report fourth quarter and full year 2025 financial results on Thursday, February 19, 2026, after U.S. market close. The company will host a conference call and webcast at 4:30 p.m. ET to discuss results and provide a business update.
Webcast and dial-in details are available on Travere's Investor page, and an archived recording will be posted for 30 days following the live event.
Travere Therapeutics (NASDAQ: TVTX) disclosed inducement equity grants made on February 10, 2026. The Compensation Committee awarded inducement restricted stock units covering an aggregate of 49,200 shares to ten new employees.
The RSUs were issued outside the 2018 Equity Incentive Plan under Nasdaq Listing Rule 5635(c)(4) and vest over four years, with 25% vesting each anniversary, subject to continued service.
Travere Therapeutics (NASDAQ: TVTX) will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 4:00 p.m. ET.
According to Travere Therapeutics, the presentation will be available via live webcast on the company investor site, with a replay accessible for up to 30 days.
Travere Therapeutics (Nasdaq: TVTX) said the FDA extended review of its supplemental NDA for FILSPARI (sparsentan) in focal segmental glomerulosclerosis (FSGS), setting a new PDUFA target action date of April 13, 2026.
The FDA deemed Travere's recent responses to requests for further characterization of clinical benefit a Major Amendment, which triggered the extension. No additional safety or manufacturing information was requested. Travere says commercial launch preparations continue in parallel. FILSPARI is already approved by the FDA and EMA for slowing kidney function decline in adults with IgA nephropathy.
Travere Therapeutics (NASDAQ: TVTX) reported preliminary, unaudited results and 2026 outlook. The company expects Q4 2025 U.S. net product sales ≈ $127M and FY2025 U.S. net product sales ≈ $410M, with year-end cash, equivalents and marketable securities of ≈ $323M. FILSPARI reached 908 new patient start forms in Q4 and delivered ~$103M of U.S. net sales in the quarter (+108% YoY). PDUFA for FILSPARI in FSGS is Jan 13, 2026 (sNDA under FDA review). The pivotal Phase 3 HARMONY study for pegtibatinase is on track to restart in 1Q 2026.
Travere Therapeutics (NASDAQ: TVTX) announced that Eric Dube, Ph.D., president and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 4:30 p.m. PT. A live webcast will be available on Travere's investor site at ir.travere.com/events-presentations, and a replay will be accessible for up to 30 days after the event.
Travere Therapeutics (NASDAQ: TVTX) announced on December 10, 2025 that its Compensation Committee granted inducement equity awards to five new employees totaling 20,300 restricted stock units (RSUs).
The RSUs were granted outside the 2018 Equity Incentive Plan as inducements under Nasdaq Listing Rule 5635(c)(4). The awards vest over four years with 25% vesting each anniversary, subject to continued service through each vesting date.
Travere Therapeutics (NASDAQ: TVTX) announced that on November 10, 2025 its Compensation Committee granted inducement restricted stock units to three new employees totaling 25,700 RSUs. The grants were made outside the company’s 2018 Equity Incentive Plan but subject to its terms as permitted under Nasdaq Listing Rule 5635(c)(4). The RSUs vest over four years with 25% vesting on each anniversary of the grant date, subject to continued service through each vesting date.
Travere Therapeutics (Nasdaq: TVTX) presented late-breaking Phase 3 DUPLEX data at ASN Kidney Week 2025 (Nov 6-9). The analyses show FILSPARI (sparsentan) patients were more likely to reach urine protein-to-creatinine ratio (UPCR) below 0.7 g/g versus maximum labeled dose irbesartan (37.5% vs 21.4%, RR 1.8).
At week 108, rates were 19% vs 11.2% (RR 1.7). DUPLEX-aligned RaDaR modeling linked achieving UPCR<0.7 g/g at 24 months to markedly lower five-year kidney-failure risk (HR 0.14); applying a 26% relative UPCR reduction for FILSPARI translated to a modeled 24% lower 5-year kidney-failure risk (HR 0.76).